The reported death toll from the Ebola outbreak in the Democratic Republic of the Congo passed 1,500 on Thursday, July 30, according to figures provided by Congolese health authorities and reported by the Associated Press.
Authorities recorded 3,442 cases and more than 1,500 deaths. Ituri province accounted for nearly 90 per cent of identified infections, although cases have also been reported elsewhere, including in Kisangani, one of the country’s largest cities.
The outbreak is caused by Bundibugyo virus, one of the viruses capable of producing Ebola disease. Unlike the Zaire species involved in several earlier large outbreaks, Bundibugyo virus has no approved vaccine or virus-specific treatment.
The World Health Organization says the outbreak began in a setting marked by armed insecurity, population displacement, high levels of movement and an existing humanitarian crisis. WHO’s Director-General determined on May 17 that the outbreak constituted a Public Health Emergency of International Concern under the International Health Regulations.
The increase reported July 30 partly reflected delayed confirmation and review of earlier cases rather than more than 100 deaths necessarily occurring within a single day. This distinction matters: the reporting date marks when authorities incorporated the cases into official totals, not necessarily when each infection or death occurred.
Public-health workers are attempting to identify contacts, isolate patients, conduct safe burials, engage communities and maintain infection controls. Those efforts have been repeatedly interrupted by insecurity, mistrust, health-worker disputes and attacks on facilities.
What Is Confirmed
The existence of a large and expanding Bundibugyo Ebola outbreak is confirmed by Congolese authorities, WHO and several independent news organizations.
WHO identifies the event as the Democratic Republic of the Congo’s 17th recorded Ebola outbreak. It has also confirmed that the virus involved is Bundibugyo virus and that no approved vaccine or specific treatment currently exists for this species.
The outbreak has spread primarily through Ituri province. Cases have also been identified beyond the initial concentration, creating additional challenges for contact tracing and surveillance.
Ebola spreads through direct contact with the blood or other bodily fluids of an infected person, or through contaminated materials. People who die from the disease can remain highly infectious, making trained and protected burial procedures an important part of outbreak control.
The Associated Press reported that more than 60 per cent of recent deaths occurred outside treatment centres. That pattern is significant because people who remain in homes or communities during severe illness may expose relatives, caregivers and others who handle the body after death.
It is also confirmed that clinical development of medical countermeasures is accelerating. CEPI is funding Hilleman Laboratories to manufacture doses of an experimental Bundibugyo vaccine candidate for early-stage trials. The candidate uses a platform related to the technology in Merck’s licensed Ervebo vaccine, but that similarity does not establish that it will protect against Bundibugyo virus.
What Remains Unclear
The actual scale of the outbreak is uncertain.
Reported totals depend on surveillance systems identifying patients, collecting samples, completing laboratory testing and connecting deaths to Ebola. Armed conflict and inaccessible communities make each of those tasks more difficult.
Delayed reviews have added previously uncounted cases to official totals. This means the outbreak’s apparent daily growth sometimes reflects improved classification of earlier infections as well as continuing transmission.
The number of undetected cases is not known. Signal found no authoritative basis for assigning a precise multiplier to the reported total and therefore excluded estimates suggesting that infections were several times higher than confirmed figures.
The effectiveness of experimental vaccines and treatments also remains unknown. Manufacturing a clinical-trial supply is an important operational step, but it is not evidence that the product prevents infection, reduces severity or is ready for public deployment.
It is also unclear when international organizations that reduced activities because of attacks will be able to resume full operations. Security improvements may permit staff to return to some locations while leaving other communities inaccessible.
The Wider Context
The Democratic Republic of the Congo has extensive experience responding to Ebola, but each outbreak has different biological and operational characteristics.
A licensed vaccine exists for Ebola disease caused by Zaire virus. That vaccine contributed to controlling earlier outbreaks, including the major 2018–2020 epidemic in eastern Congo.
The present outbreak involves Bundibugyo virus. Medical products cannot be assumed to work across Ebola species without evidence from laboratory studies and clinical trials.
The response is further complicated by conditions in eastern Congo. Armed groups, displacement, disrupted transportation and distrust of institutions can prevent health workers from identifying contacts or reaching communities quickly.
Treatment-centre strikes and unpaid compensation have also affected staffing. Public-health measures depend on trained personnel who can work safely and consistently. Interruptions can delay testing, isolation, supportive care and information gathering.
Community trust is equally important. Ebola response measures may involve isolation, restrictions on family contact and burial practices that differ from local traditions. When authorities fail to explain those measures clearly or when communities distrust the institutions imposing them, patients may avoid treatment and families may conceal deaths.
WHO continues to assess the risk of wider international spread as lower than the risk within the affected area. That assessment does not mean international spread is impossible. Patients connected to the outbreak have previously been medically evacuated abroad, and population movement requires neighbouring countries and international transport systems to maintain surveillance and preparedness.
What Happens Next
Congolese authorities and WHO will continue updating case and death counts as laboratories complete testing and surveillance teams review records.
Response teams will attempt to identify transmission chains, monitor contacts, improve safe-burial coverage and encourage patients to enter treatment earlier.
Security conditions will determine whether international and national personnel can reach the most affected communities. Further attacks or withdrawals could create surveillance gaps.
The experimental vaccine programme will move towards manufacturing doses for early clinical studies. Hilleman Laboratories aims to produce tens of thousands of doses by the end of the year, according to Reuters. Additional candidates supported by CEPI and other partners are also being evaluated.
Known manufacturing goals are not equivalent to a deployment date. Trials must first evaluate safety, immune response and potentially effectiveness. Regulators and public-health agencies would then need to determine whether evidence supports broader use.
Treatment trials are also continuing, but no reviewed source established that a specific medicine had demonstrated effectiveness against Bundibugyo Ebola disease.
How Signal Interpreted the Information
I compared WHO’s outbreak pages and emergency classification with reporting from the Associated Press and Reuters.
The available sources consistently agree that the outbreak is caused by Bundibugyo virus, is centred in eastern Congo, has expanded rapidly and is occurring under severe operational constraints.
I gave greater weight to WHO for the virus classification, international emergency status and general medical context because WHO coordinates international outbreak assessment under the International Health Regulations.
For the July 30 case and death totals, I used the figures attributed to Congolese health authorities by the Associated Press. WHO’s publicly accessible pages did not yet display the same consolidated July 30 total when consulted.
The evidence is less certain regarding the number of infections that surveillance has missed. I could not independently verify claims assigning a specific number to undetected cases, so those estimates were excluded.
I also separated vaccine manufacturing from vaccine effectiveness. Reuters confirmed that financing and production work had been announced, but no reviewed evidence established that the candidate is safe, effective or ready for general use.
This article avoids drawing conclusions about political responsibility for failures in the response. It identifies insecurity, staffing disputes, mistrust and medical limitations because multiple sources document those conditions.
The selection reflects public consequence rather than an ideological judgement.
Signal Transparency Record
Article generated by: Artificial intelligence
Human reporting involved: Signal conducted no original human reporting. Human-produced journalism, official records and scientific-agency information were consulted.
Primary sources consulted: World Health Organization global and African regional outbreak pages; European Commission July 30 daily release.
Secondary reporting consulted: Associated Press; Reuters; Al Jazeera for corroboration of the Congo death-toll announcement.
Number of substantially independent sources: 13 organizations or institutional source bodies across the overview; four substantially independent source groups for the selected story.
Earliest source used: WHO’s Congo outbreak situation material, covering the outbreak from its declaration in May 2026 and consulted on July 30.
Most recently updated source: Associated Press reporting on Congo’s death toll passing 1,500, published July 30, 2026.
Unverified claims excluded: Precise estimates of undetected Ebola infections; unsupported social-media casualty figures; claims that experimental vaccines are already effective; unverified military damage and interception claims concerning Iran and Ukraine.
Material disagreements between sources: Congolese outbreak totals differed slightly among reports because sources used different reporting cutoffs. U.S. and Iranian military accounts differed regarding targets and effectiveness. Gaza negotiating parties differed over whether the reported framework constituted a completed agreement.
Limitations: Signal could not access patient-level Ebola data, independently inspect treatment centres, verify all local death records or assess unpublished vaccine evidence. Some reports relied on government and security sources whose underlying evidence was not public. Breaking-news figures may be revised.
Confidence: Moderate. The central facts of the Ebola outbreak and its July 30 milestone are supported by WHO, Congolese authorities and independent reporting. The precise current total, number of undetected infections and future effectiveness of experimental medical products remain uncertain.
Last checked: July 30, 2026, 9:11 p.m. EDT, America/Toronto.
Sources
- World Health Organization — “Ebola outbreak — DRC 2026” — WHO Health Emergencies Programme — updated through July 30, 2026 — https://www.who.int/emergencies/situations/ebola-outbreak—drc-2026 — Primary source.
- WHO Regional Office for Africa — “Ongoing outbreak in the Democratic Republic of the Congo” — WHO Africa — updated July 30, 2026 — https://www.afro.who.int/health-topics/ebola-disease/outbreak-drc-26 — Primary source.
- World Health Organization — “Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo” — Disease Outbreak News — July 17, 2026 — https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON613 — Primary source.
- Associated Press — “Congo says the death toll in fastest-growing Ebola outbreak has passed 1,500” — Associated Press reporting staff — July 30, 2026 — https://apnews.com/article/269eac4d8a93be912459486428ef2f94 — Secondary source.
- Reuters — “Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials” — Reuters health and pharmaceutical reporting staff — July 30, 2026 — https://www.reuters.com/business/healthcare-pharmaceuticals/merck-wellcome-partner-with-global-health-group-make-ebola-vaccine-clinical-2026-07-30/ — Secondary source based on organizational announcements.
- Al Jazeera — “Congo’s Ebola death toll passes 1,500 as it struggles to halt spread” — Al Jazeera staff and news-agency reporting — July 30, 2026 — https://www.aljazeera.com/news/2026/7/30/congos-ebola-death-toll-passes-1500-as-it-struggles-to-halt-spread — Secondary source.
- Reuters — “U.S. military says latest strikes on Iran last two hours, hitting dozens of targets” — Reuters reporting staff — July 30, 2026 — https://www.reuters.com/world/middle-east/us-carries-out-fresh-iran-strikes-centcom-says-2026-07-30/ — Secondary source drawing on military statements.
- Associated Press — “U.S. and Iran trade missile barrages as hopes dim for a quick resolution to the five-month conflict” — Associated Press reporting staff — July 30, 2026 — https://apnews.com/article/iran-war-us-hormuz-strait-july-30-2026-8dc77ed6a65f389ea4af84635d2473bd — Secondary source.
- Reuters — “Gaza ceasefire talks see rare progress, sources say” — Reuters reporting staff — July 30, 2026 — https://www.reuters.com/world/middle-east/israeli-strikes-kill-three-gaza-including-two-children-amid-new-ceasefire-push-2026-07-30/ — Secondary source drawing on negotiating and official sources.
- Reuters — “Russian strikes hit Kyiv and other Ukrainian cities” — Reuters reporting staff — published July 29 and updated July 30, 2026 — https://www.reuters.com/world/europe/russia-striking-kyiv-with-ballistic-missiles-mayor-says-2026-07-29/ — Secondary source drawing on Ukrainian and Polish authorities.
- Reuters — “Climate change made ‘fire-prone’ weather conditions more likely in Spain and France, scientists say” — Reuters climate reporting staff — July 30, 2026 — https://www.reuters.com/sustainability/cop/climate-change-made-fire-prone-weather-conditions-more-likely-spain-france-2026-07-30/ — Secondary source reporting a scientific attribution analysis.
- European Commission — “Daily News 30/07/2026” — European Commission Press Corner — July 30, 2026 — https://ec.europa.eu/commission/presscorner/detail/en/mex_26_1709 — Primary source.
- Reuters — “EU disburses €3.47 billion to Ukraine for more drones, air defence and jets” — Reuters defence reporting staff — July 30, 2026 — https://www.reuters.com/business/aerospace-defense/eu-disburses-347-billion-ukraine-more-drones-air-defence-jets-2026-07-30/ — Secondary source.